Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Dr Takeyama Stresses Need to Educate Public about OAB
October 9, 2006
- TOPICS／Pfizer Commits US$15 Mil. to Protect African Children from Malaria
October 9, 2006
- Hakuo Yanigasawa Appointed Minister of Health
October 9, 2006
- New Head of METI to Push for Strong Economic Growth
October 9, 2006
- New Head of MOF to Reconstruct Finance by Stimulating Economy
October 9, 2006
- IPHC Rules in Favor of 3 Generic Houses in Lawsuit over Selbex Appearance
October 9, 2006
- CDFS's Department on Drugs Recommends Approval of 16 Drugs
October 9, 2006
- Five Walls Hindering Greater Use of Generic Drugs: Prof Mutoh
October 9, 2006
- HSB to Place Top Priority on Fight Against Cancer
October 9, 2006
- GENERICS NEWS IN BRIEF
October 9, 2006
- PFSB to Prepare for Full Implementation of Amended PAL, Reduce "Drug Lag"
October 9, 2006
- 65th Annual Meeting of Japanese Cancer Association (1)
October 9, 2006
- REGULATORY NEWS IN BRIEF
October 9, 2006
- Clinical Trial Study Group Discusses Way to Lighten Sponsors' Burden
October 9, 2006
- CMIC Begins CRF Checking Services
October 9, 2006
- PMDA to More Closely Cooperate with Other Asian Countries: Mr Miyajima
October 9, 2006
- FTC Survey Faults New Drug Makers for Misleading Info. on Generics
October 9, 2006
- R&D NEWS IN BRIEF
October 9, 2006
- Expert Sees Legal Risk in Limited-Facility, All-case PMS
October 9, 2006
- MEDICAL DEVICE NEWS IN BRIEF
October 9, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…